Speeding Diagnosis & Predicting Survival Outcomes With AI : Oncology Times
An abstract is unavailable.
Related Articles
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Pertuzumab Biosimilar BLA for HER2+ Breast Cancer Accepted by FDA
After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study
PURPOSEApproximately 50% of patients with advanced Merkel cell carcinoma (MCC) have primary or acquired resistance to PD-(L)1 blockade, which may be overcome using combination immune…
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
FDA Grants Breakthrough Device Designation to Serial CTRS AI Model for NSCLC
The FDA has granted breakthrough device designation to Serial CTRS for risk prognosis in non–small cell lung cancer.
MD Anderson Study Resumes With Seclidemstat/Azacitidine in MDS/CMML
The combination of seclidemstat and azacitidine will resume study in a phase 1/2 trial in patients with MDS and CMML following a partial clinical hold.
Fungal Influences on Cancer Initiation, Progression, and Response to Treatment
Abstract. Fungal dysbiosis is increasingly recognized as a key factor in cancer, influencing tumor initiation, progression, and treatment outcomes. This review explores the role of…
Abstracts – 2025 ASTRO Annual Meeting – American Society for Radiation Oncology (ASTRO)
The Annual Meeting program will deliver the top science and education related to the field of radiation oncology.
